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red blood cells compared with clopidogrel or controls (p < 0.01 for both comparisons). Adenosine deaminase
activity was similar in serum of patients receiving clopidogrel or ticagrelor (p ¼ 0.1). Ticagrelor and clopidogrel had
no direct impact on adenosine receptors (p ¼ not signiﬁcant).Conclusions Ticagrelor increases APC in ACS patients compared with clopidogrel by inhibiting adenosine uptake by red blood
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evised manuscript received September 18, 2013,diphosphate (ADP) receptor blocker that has demonstrated
higher biological efﬁcacy than clopidogrel (1). Its higher
potency led to improved prognosis in acute coronarySee page 878syndrome (ACS) patients (2). Interestingly, unlike in
previous trials of P2Y12-ADP receptor blockers, in the
PLATO (Platelet Inhibition and Patient Outcomes) trial
the beneﬁt of ticagrelor has continued to grow, and cardio-
vascular mortality has been signiﬁcantly reduced (2–4).
These observations led to the hypothesis that ticagrelor has
pleiotropic properties and suggested some novel nonplatelet-
directed mechanisms of action.
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and Acronyms
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ADA = adenosine deaminase
activity
ADP = adenosine
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APC = adenosine plasma
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cAMP = cyclic adenosine
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MFI = mean ﬂuorescence
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PG = prostaglandin
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873Adenosine is released in the plasma by endothelial cells
and myocytes during ischemia, hypoxia, or oxidative stress
(5,6). Most of the plasma adenosine is quickly taken up
by red blood cells (RBC) through a facilitated diffusion
transport system (7) or converted into inosine by adenosine
deaminase activity (ADA) (8). An increase in APC may,
therefore, result from the inhibition of RBC uptake, reduced
ADA, or both. Increased APC impacts the cardiovascular
system by purinergic receptors, named A1, A2A, A2B, or A3
depending on their pharmacological properties (9).
In experimental studies, ticagrelor has been shown to
increase adenosine-induced physiological response by shifting
the dose-response curve for adenosine-induced coronary
blood ﬂow velocity to the left (10). In addition, in vitro
experiments suggested that ticagrelor inhibited adenosine re-
uptake by human RBC (11). However, these observations
weremade in a dogmodel and in vitro. Therefore, we aimed to
investigate in ACS patients the effects of ticagrelor on APC.
Methods
We performed a single-center, prospective, open-label,
randomized trial enrolling patients with intermediate- or
high-risk non–ST-segment elevation ACS. Twenty healthy
subjects without medication (12 men and 8 women) from
our medical staff served as control group.
The present study was approved by the institutional
review board and agrees with the declaration of Helsinki. All
patients gave informed consent. They were randomly allo-
cated to ticagrelor or clopidogrel according to a sequence
generated using R software (blockrand package, R Foun-
dation for Statistical Computing, Vienna, Austria).
Blood samples were collected before coronary angiog-
raphy and 6 h after a P2Y12-ADP receptor antagonist
loading dose.
For antiplatelet therapy, a loading dose of 180 mg tica-
grelor followed by 90 mg twice-daily was used in the tica-
grelor group, and a loading dose of 600 mg clopidogrel
followed by 75 mg daily was used in the clopidogrel group.
In addition, all patients received a loading dose of 250 mg
aspirin followed by 75 mg daily.
Exclusion criteria were New York Heart Association
functional class greater than or equal to III, cardiac arrest,
contraindications to antiplatelet therapy, treatment with
a P2Y12-ADP receptor antagonist for <1 month, a platelet
count <100 g/l, history of bleeding diathesis, history of
hemorrhagic stroke, stroke in the preceding year, recent
surgery (preceding month), use of medication having known
interference with ticagrelor, and bradycardia.
Vasodilator-stimulated phosphoprotein measurement.
The vasodilator-stimulated phosphoprotein (VASP) index
phosphorylation analysis was performed within 24 h of
blood collection using platelet VASP kits (Diagnostica
Stago, Asnières, France) (12). TheVASP index was calculated
from the mean ﬂuorescence intensity (MFI), assessed by ﬂow
cytometry, of samples incubated with either prostaglandin(PG) E1 or PGE1 and ADP
according to the following for-
mula: VASP ¼ [(MFI(PGE1) 
MFI(PGE1þADP)) /MFI(PGE1)]
100. Patients with a VASP
index 50% were considered to
have high on-treatment platelet
reactivity (PR) (13).
Adenosine plasma concentration
measurement. Blood samples
(3 ml) were collected and pro-
cessed as described (14,15). Fresh
whole blood was collected in
tubes containing a stop solution
to prevent RBC uptake and
degradation of adenosine by
ADA. The stop solution is re-
quired to prevent adenosine deg-
radation, which is very quick
otherwise. The stop solution was
composed of dipyridamole, 0.2 mM; ethylenediaminetetra-
acetic acid disodium, 4 mM; erythro-9-(2-hydroxy-3-nonyl
adenine), 5 mM; alpha,beta-methyleneadenosine 50-diphos-
phate, 79 mM; 20-deoxycoformycin, 10 mg/ml; and heparin
sulfate, 1 IU/ml. After centrifugation, supernatants were
deproteinized, and APC was measured by high-performance
liquid chromatography, as previously described (14,15).
Adenosine deaminase activity. Fresh serum was pipetted
off after centrifugation of whole blood. The ADA was
evaluated by the ammonium formed (Beckman DX, Beck-
man Coulter, Brea, California) after incubation (40 min at
37C) of 125 ml serum with 750 ml adenosine (28 mM), as
previously described (16).
Adenosine uptake by RBC. Samples of fresh whole blood
(1 ml) of patients and controls were collected on ethyl-
enediaminetetraacetic acid tubes without stop solution.
Then, 1 nmol of adenosine was added. Samples were
continuously mixed with a vortex mixer for 60 s. Uptake by
RBC was stopped by adding 500 ml cold stop solution
at time 0 (T0) and after 15 s (T15), 30 s (T30), and 60 s
(T60). Samples were immediately centrifuged (4C, 1,500g
for 10 min), and APC was measured (15–17).
Adenosine receptor activity. To evaluate a potential
adenosine receptor’s agonist property of ticagrelor or clopi-
dogrel derivatives, we assessed the impact of the serum of
patients on cyclic adenosine monophosphate (cAMP)
production of recombinant cell lines overexpressing the A1
or A2A receptor (CHO Chem 3 cells, Millipore, Billerica,
Massachusetts).
Cyclic AMP concentration determination. Fresh serum
of patients and controls were pipetted off after centrifugation
of whole blood. No stop solution was used as adenosine is
quickly degradated by ADA, thus allowing assessment of
the ability of drug derivatives to act on receptors. Modula-
tion of cAMP production by the patient’s serum was tested
and compared with serum controls and with serum
Table 1 Baseline Characteristics of Study Population
Ticagrelor (n ¼ 30) Clopidogrel (n ¼ 30) p Value
Age, yrs 62  12 64  12 0.5
Male 23 (76.7) 22 (73.3) 0.9
Body mass index, kg/m2 27.8  5.1 27.6  4.6 0.8
Cardiovascular risk factors
Smoking 9 (30) 7 (23.3) 0.8
Hypercholesterolemia 17 (56.7) 21 (70) 0.5
Diabetes mellitus 11 (36.7) 12 (40) 0.9
Hypertension 15 (50) 16 (53.3) 0.9
Family history of CAD 7 (23.3) 5 (16.7) 0.6
Clinical setting
NSTEMI 19 (63.3) 19 (63.3) 1
Unstable angina 11 (36.7) 11 (36.7)
Medication on admission
Proton pump inhibitor 10 (34.5) 10 (34.5) 1
Aspirin 7 (24.1) 14 (46.7) 0.1
Beta-blocker 8 (27) 10 (34.5) 0.6
Statin 12 (40) 12 (40) 1
Angiography and intervention
Number of diseased vessels
1 14 (46.7) 8 (26.7) 0.8
2 7 (23.3) 13 (43.3)
3 9 (30) 9 (30)
Biology
Leukocytes, g/l 9.4  3.3 8.6  2.8 0.4
Hemoglobin, g/dl 14  1.8 13.8  19 0.7
Platelets, 103/l 247  64 243  44 0.7
Fibrinogen, g/l 3.6  1 3.6  0.8 0.9
Creatinine, mmol/l 90  24 89  27 0.8
CRP, mg/l 12.3  18 17  20 0.4
VASP index, % 16.5  15 46.9  22.3 <0.0001
Values are mean  SD or n (%).
CAD ¼ coronary artery disease; CRP ¼ C-reactive protein; NSTEMI ¼ non–ST-segment elevation myocardial infarction; VASP ¼ vasodilator-
stimulated phosphoprotein.
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874containing cyclopentyladenosine (CPA), an A1 receptor
agonist, or CGS21680, an A2A receptor agonist, in a nano-
molar concentration. The cAMP concentration was deter-
mined by immunoassay (cAMP Biotrak EIA, Amersham,
Orsay, France), as previously described (18).
C-reactive protein. To evaluate a potential link bet-
ween inﬂammation and adenosine metabolism, we measured
C-reactive protein (CRP) using Beckman DX apparatus.
Clinical endpoints. Major adverse cardiovascular events,
including cardiovascular death, myocardial infarction, urgent
revascularization, and stroke at 1 month, were recorded.
Bleeding was measured using the TIMI (Thrombolysis In
Myocardial Infarction) study classiﬁcation. Dyspnea was
also recorded.
Statistical analysis. Analyses were performed with R free
software, version 2.8.1 (R Foundation for Statistical
Computing). Continuous variables are expressed asmean SD
or median and interquartile range (IQR). They were compa-
red using the nonparametric Mann-Whitney U test. The
nonparametric Wilcoxon test was used for intraindividual
comparisons. Multiple comparisons were made among the4 groups using the multiple comparisons Mann-Whitney
U test with Bonferroni corrections. Spearman’s r coefﬁcient
of correlation was used for correlation studies.
Results
The baseline characteristics of the study population are given
in Table 1.
APC after P2Y12-ADP receptor loading dose. The APC
was more than 2-fold higher in patients taking ticagrelor
than in patients taking clopidogrel (1.5 mM [IQR: 0.98 to
1.7 mM] vs. 0.68 mM [IQR: 0.49 to 0.78 mM]; p < 0.01) or
controls (0.6 mM [IQR: 0.5 to 0.8 mM]; p < 0.01) (Fig. 1).
No statistical difference was observed between patients
under clopidogrel and controls.
Mechanism of APC increase. EFFECTS OF PATIENTS’
SERUM ON ADA. The patients in the 2 treatment groups did
not differ signiﬁcantly regarding ADA (p ¼ 0.1). The ADA
was higher in serum of patients in the ticagrelor group and
clopidogrel group (15 IU [IQR: 12.6 to 18.2 IU] and 13.5
IU [IQR: 12 to 16 IU], respectively) than in control subjects
Figure 3 Correlation Between ADA and CRP
Correlation (Spearman’s r) between adenosine deaminase activity (ADA) and
C-reactive protein (CRP).
Figure 1
Comparisons of APC in Ticagrelor, Clopidogrel,
and Control Groups
*Indicates p < 0.01 for ticagrelor group versus control group or clopidogrel group.
APC ¼ adenosine plasma concentration.
JACC Vol. 63, No. 9, 2014 Bonello et al.
March 11, 2014:872–7 Ticagrelor Increases Plasma Adenosine in ACS
875(8 IU [IQR: 7.1 to 9 IU]; p < 0.01 for both groups) (Fig. 2).
The ADA weakly correlated with CRP (r ¼ 0.47; p < 0.01)
(Fig. 3).
EFFECTS OF PATIENTS’ SERUM ON CAMP PRODUCTION. Re-
garding the production of cAMP by cells expressing the
adenosine receptors, no difference was observed between
serum of patients in the ticagrelor group and in the clopi-
dogrel group compared with controls (p ¼ 0.7 and p ¼ 0.1
for A1 receptors, respectively; and p ¼ 0.6 and p ¼ 0.1
for A2A receptors, respectively) (Fig. 4).Figure 2 ADA of Serum-Containing Drugs
Deoxycoformycin was used as adenosine deaminase activity (ADA) inhibition
control value. *Indicates p < 0.01 control group versus ticagrelor or clopidogrel
group.EFFECTS OF PATIENTS’ SERUM ON ADENOSINE UPTAKE BY RBC.
Ticagrelor signiﬁcantly inhibited adenosine uptake by RBC
compared with clopidogrel (p < 0.001 at all times) and with
controls (p < 0.001 at all times). Clopidogrel did not impact
adenosine uptake by RBC compared with controls (p ¼ not
signiﬁcant at all times) (Fig. 5).
PR and relationship with APC. Ticagrelor induced
a signiﬁcantly higher PR inhibition than clopidogrel, as
measured by the VASP index, after P2Y12-ADP receptor
loading dose (14.7% [IQR: 9.2% to 19.8%] vs. 44% [IQR:
33.5% to 64.2%]; p < 0.001). The rate of patients with
high on-treatment PR after ticagrelor loading dose was
signiﬁcantly lower compared with clopidogrel loading dose
(3% vs. 40%; p < 0.001). Finally, PR inhibition and
adenosine plasma concentration were not correlated (r ¼
0.27; p ¼ 0.2).
Clinical endpoints. No ischemic or bleeding events were
recorded within 1 month. Dyspnea was present in 7 patients
in the ticagrelor group and in 5 patients in the clopidogrel
group (p ¼ 0.6).Discussion
The present study is the ﬁrst to demonstrate a signiﬁcant
increase in APC in ACS patients treated with ticagrelor
compared with clopidogrel. In addition, we observed that
this property of ticagrelor was related to the inhibition of
adenosine uptake by RBC. These ﬁndings demonstrate that
ticagrelor has signiﬁcant off-target properties in ACS
patients through a direct action on APC. Finally, in line
with previous studies, ticagrelor achieved a more potent PR
inhibition compared with clopidogrel as measured by the
VASP index (1).
Figure 4
Production of cAMP by Chem Cells Overexpressing
A1 or A2A Receptors
Production of cyclic adenosine monophosphate (cAMP) production in the presence
of serum of patients treated with clopidogrel or ticagrelor or with serum control
subjects was similar for the A1 and A2A receptors. Cyclopentyladenosine (CPA)
inhibited, whereas CGS21680 increased, cAMP production.
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suggested that ticagrelor increases an adenosine-induced
physiological response by shifting the dose-response curve
for adenosine-induced coronary blood-ﬂow velocity to the
left (10). Accordingly, in an animal experiment, van Giezen
et al. (11) observed that ticagrelor enhances adenosine-
mediated responses on coronary blood ﬂow. Furthermore,Figure 5 Effects of Drugs on Adenosine Uptake by RBC
At all times, serum of patients receiving ticagrelor (solid squares) was associated
with a higher adenosine plasma concentration compared with the serum of
clopidogrel patients (open triangles) or control subjects (solid triangles). Open
circles ¼ stop solution. *p < 0.001 ticagrelor group versus clopidogrel group.
RBC ¼ red blood cells.those researchers suggested that this effect may be related
to the inhibition of adenosine uptake by RBC. Consistent
with these preliminary ﬁndings, the present study demon-
strated that ticagrelor increased APC in ACS patients.
Our study has several additional originalities. First, it was
performed in ACS patients, and thus it accurately reﬂects
the effect of ticagrelor in patients with ischemia and coro-
nary artery disease. Second, we compared ticagrelor with
clopidogrel, unlike previous studies that used placebo as
control value (10). Finally, we also focused on the mecha-
nism of APC increase. In the present study, this property of
ticagrelor over APC was independent of P2Y12-ADP
receptor blockade. The serum of patients treated with tica-
grelor had no direct effect on adenosine receptor A1 or A2A
and did not affect ADA. Finally, we demonstrated that the
serum of ACS patients treated with ticagrelor inhibited
adenosine uptake by RBC, leading to the increase in APC
similar to what was observed for dipyridamole (19,20).
The present results suggest that the “pleiotropic” prop-
erties of ticagrelor could in part be mediated by the increased
APC. Adenosine has multiple properties involving blood,
vessels, and ischemic damage. First, it inhibits platelet
aggregation through the activation of A2A receptors.
Second, several lines of evidence conﬁrmed the vasodilatory
properties of adenosine on arterial beds (21). These prop-
erties could be related to the activation of low-afﬁnity A2A
receptors through the increase in APC, as these receptors
are strongly implicated in coronary blood ﬂow regulation
(21,22). Accordingly, the APC level measured in the pre-
sent study in the ticagrelor group is compatible with the
activation of the adenosine A2A low afﬁnity receptors (21).
These properties of adenosine may be particularly important
in the context of diseased vessels and hypoxia associated
with ACS. However, the role of adenosine in protection of
the ischemic heart remains controversial, and the long-term
impact of high APC on coronary artery disease remains to
be determined (23).
Ticagrelor was shown to have speciﬁc side effects, brady-
cardia and dyspnea, which could also be triggered by APC
increase (2). However, the present study was not powered
to explore a link between APC and these side effects.Conclusions
Ticagrelor is associated with a signiﬁcant increase in APC in
ACS patients that is related to the inhibition of adenosine
re-uptake by RBC. This property of ticagrelor on APC may
be responsible for the so-called “pleiotropic” properties of
the drug and may contribute to its side effects.
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